Increasingly, pharma and biotech companies are looking towards personalized medicine to guide their portfolios, developing therapies designed to address the needs of individual patient populations.
Nanobiotix (EMA:NANO) has chosen to look in the other direction, according to co-founder & CEO Laurent Levy.
“What we have done in our company is trying to go for the opposite: to find 1 product that could potentially help millions of patients,” Levy told Drug Delivery Business News.
Get the full story at our sister site, Drug Delivery Business News.
The post Nanobiotix seeks to boost cancer care with nanoparticle-radiotherapy combo appeared first on MassDevice.
from MassDevice http://ift.tt/2rKROqf
Cap comentari:
Publica un comentari a l'entrada